Celea Therapeutics completes $180 million financing, supported by RA Capital, Leaps by Bayer, and PureTech Health, to advance deupirfenidone for IPF treatment.
Amount Raised
$180 Million
Round Type
Funding Round
BostonBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
Celea Therapeutics has announced the completion of a $180 million financing to support the initiation of the Phase 3 SURPASS-IPF trial for deupirfenidone. The financing includes participation from notable investors such as RA Capital Management, Leaps by Bayer, and PureTech Health. This funding will enable Celea to evaluate the potential of deupirfenidone as a new standard of care for idiopathic pulmonary fibrosis. The trial is set to begin in early Q3 2026.
Quick answer
Celea Therapeutics raised $180 Million in a Funding Round round, dated July 2, 2026. Investors: PureTech Health, Leaps By Bayer and RA Capital Management. Celea Therapeutics is based in Boston, Massachusetts, United States.
- How much did Celea Therapeutics raise?
- Celea Therapeutics raised $180 Million in a Funding Round round on July 2, 2026.
- Who invested in Celea Therapeutics?
- PureTech Health, Leaps By Bayer and RA Capital Management are named as investors in this round.
- What does Celea Therapeutics do?
- Celea Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases.
- Where is Celea Therapeutics based and how big is it?
- Celea Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 27 employees.
- Who are the decision-makers at Celea Therapeutics?
- Fundz holds 1 contact at Celea Therapeutics, including the President & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Celea Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Apollomics raised $10M on August 14, 2026.
- Vaderis Therapeutics raised $152M (Series B) on August 11, 2026.
- Os Therapies raised $5M on August 10, 2026.
- Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
- Acasti raised $10M on August 4, 2026.
- HCW Biologics raised $1.5M (Post-IPO Equity) on July 29, 2026.
Who to call at Celea Therapeutics, and when
A new round usually means Celea Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Celea Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Celea Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Celea Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Celea Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Celea Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.